Physician profile
Matthew Meriwether
NPI 1902253081
$8,445.92
in general payments reported to CMS, 2019-2025
40 companies · $1,878 in 2025
The $1,878 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $235 · 2021: $598 · 2022: $1,079 · 2023: $2,319 · 2024: $2,338 · 2025: $1,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,534.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,292.86 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $794.96 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Qol Medical, LLC | $645.03 | 2022-2025 | Sucraid, Sucraid |
| Celgene Corporation | $472.01 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $381.78 | 2023-2025 | Stelara, Tremfya, Remicade |
| Ardelyx, INC. | $295.01 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $278.49 | 2022-2024 | Ocaliva |
| Janssen Scientific Affairs, LLC | $235.24 | 2024-2025 | Stelara, Tremfya |
| Pfizer INC. | $226.61 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $221.08 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $220.10 | 2021-2025 | Gattex, Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $189.43 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $187.55 | 2024-2025 | Voquezna |
| Myriad Women'S Health, INC. | $179.98 | 2023 | Colaris, Myrisk |
| Gilead Sciences, INC. | $177.39 | 2024-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $157.40 | 2024-2025 | Zenpep |
| Genzyme Corporation | $153.04 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $149.58 | 2024-2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $133.93 | 2022-2023 | Rebyota |
| Lilly USA, LLC | $127.72 | 2023-2024 | Omvoh |
| Celltrion USA INC. | $121.34 | 2024-2025 | Vegzelma |
| Johnson & Johnson Health Care Systems INC. | $110.79 | 2022-2023 | Stelara |
| Merck Sharp & Dohme LLC | $84.01 | 2022-2024 | Dificid |
| Corium, LLC | $70.70 | 2022 | |
| Ironwood Pharmaceuticals, INC | $69.20 | 2023-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $68.46 | 2022-2023 | |
| Zest Holdings, LLC | $61.93 | 2025 | |
| Daiichi Sankyo INC. | $54.21 | 2022 | |
| Vivus LLC | $43.71 | 2023 | Pancreaze |
| Evoke Pharma, INC. | $42.34 | 2023-2024 | Gimoti |
| Olympus America INC. | $37.96 | 2021 | |
| Boston Scientific Corporation | $26.61 | 2021 | |
| Lucid Diagnostics INC. | $24.06 | 2024 | |
| Novo Nordisk INC | $20.22 | 2025 | Wegovy |
| Alfasigma USA, INC. | $16.74 | 2020 | |
| Medtronic, INC. | $16.63 | 2023 | Pillcam |
| Sandoz INC. | $14.99 | 2023 | Hyrimoz |
| Orphalan INC | $14.75 | 2025 | Cuvrior |
| Pharmacosmos Therapeutics INC. | $14.06 | 2023 | Monoferric |
| Redhill Biopharma INC. | $14.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Meriwether listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.